worldpharmaceuticals.net
Cure8 news brief
J&J secures FDA approval for Tremfya to treat Crohn's disease
Medications
Guselkumab
IL-23 inhibitor
FDA Approval
Adult patients
Patients On Biologics
Clinicians
Researchers
Why This Matters
An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did not respond to other therapies.
Who Should Pay Attention
Adults with Crohn’s disease, especially those considering or on biologic therapies; gastroenterologists and IBD clinicians; researchers following IL-23 treatments.
Study Snapshot
Story typeResearch news
Evidence typeFDA Approval
Source depthFull source text
What To Know
The FDA has approved Tremfya (guselkumab) for adults with active Crohn’s disease. The article reports that Tremfya is an IL-23–targeting monoclonal antibody with both subcutaneous and intravenous induction options, and lists the induction and maintenance dosing regimens described by the manufacturer.
The approval is supported by multiple Phase 3 trials (named GRAVITI and GALAXI in the article) including more than 1,300 patients and pooled analyses reportedly comparing Tremfya with ustekinumab (Stelara). The article also notes Tremfya was previously approved for ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
If you currently take biologic therapy, this approval represents a new, FDA-authorized IL-23 option for Crohn’s disease with a fully subcutaneous induction regimen available. Discussing suitability, switches, or dosing with your gastroenterology team is appropriate before making any changes.
The original article is an industry news piece summarizing the regulatory announcement and company comments; it does not provide full trial data or independent expert analysis.
Keep In Mind
This is a news summary of the FDA approval and company statements; the article cites Phase 3 trials but does not include full efficacy or safety data. Patients should consult their clinicians and review the primary trial publications or prescribing information for detailed data and individual suitability.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationworldpharmaceuticals.net
Indexed viaGoogle News
Source typeResearch news
PublishedMar 21, 2025, 12:19 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
USFDA nod to JnJ Tremfya for Crohn's disease
An FDA approval means a new, approved IL‑23 inhibitor option (guselkumab/TREMFYA) is available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices and offering a fully...
TREMFYA receives positive CHMP opinion for treatment of patients with Crohn's
If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.